BioPharmSignal logoBioPharmSignal

Company Profile

Kiora Pharmaceuticals Stock Price, News & Catalysts

Ticker:
KPRX
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

2.67 USD (+2.69%)

Close

Last updated: September 17, 2026

12.1M USD

Market cap

Why the stock is moving

As of Sep 17, 2026, KPRX closed up 2.69% at $2.67. No new same-company headline was identified in the current news window.

Company overview

Retinal-Disease Pipeline

Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches.

KIO-301

KIO-301 is a light-sensitive small molecule intended to restore visual signaling in patients with inherited retinal degeneration by conferring light responsiveness on surviving retinal cells. It is being evaluated in the Phase 2 ABACUS-2 study.

Additional Ophthalmic Program

Kiora's pipeline also includes a second clinical retinal program supported through collaboration funding, giving the company multiple opportunities to test its small-molecule approach in serious eye disease.

Future catalysts

    Recent news

    1. 01

      Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

    2. 02

      Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

    3. 03

      Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    4. 04

      Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

    5. 05

      Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    ABVC

    ABVC BioPharma, Inc.

    ADVM

    Adverum Biotechnologies

    ALC

    Alcon Inc.

    ALDX

    Aldeyra Therapeutics, Inc.

    ALIM

    Alimera Sciences

    APLS

    Apellis Pharmaceuticals

    BLTE

    Belite Bio

    CLSD

    Clearside Biomedical

    Frequently Asked Questions

    What is the current stock price of Kiora Pharmaceuticals (KPRX)?

    Kiora Pharmaceuticals (KPRX) most recently closed at 2.67 USD, a +2.69% move versus the previous session.

    What is the market cap of Kiora Pharmaceuticals (KPRX)?

    Kiora Pharmaceuticals currently has a market capitalization of 12.1M USD on BioPharmSignal.

    What does Kiora Pharmaceuticals do?

    Retinal-Disease Pipeline Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches. KIO-301 KIO-301 is a light-sensitive small molecule intended to restore visual signaling in patients with...

    On which exchange is KPRX stock listed?

    Kiora Pharmaceuticals (KPRX) is associated with NASDAQ, United States, Biopharma.

    What is KIO-301?

    KIO-301 KIO-301 is a light-sensitive small molecule intended to restore visual signaling in patients with inherited retinal degeneration by conferring light responsiveness on surviving retinal cells.

    Which conditions is Kiora Pharmaceuticals targeting with KIO-301?

    Retinal-Disease Pipeline Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches. KIO-301 KIO-301 is a light-sensitive small molecule intended to restore visual signaling in patients with...

    What is ABACUS-2?

    It is being evaluated in the Phase 2 ABACUS-2 study.

    What is Retinal-Disease?

    Retinal-Disease Pipeline Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases.